database / hormone
Cetrorelix
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 25074887. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
GnRH antagonist built from multiple non-proteinogenic and D-amino acids.
Molecular data
| molecular formula | C70H92ClN17O14 |
|---|---|
| molecular weight | 1431 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous |
| PubChem CID | 25074887 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Competitive GnRH receptor antagonist; suppresses LH without an initial flare.
Reported targets: GnRHR
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| LH suppression | A new cetrorelix-based estrogen-free ovarian synchronization protocol for fi… Theriogenology 2026 |
| assisted-reproduction outcomes in trials | Cetrorelix suppresses the dominant follicle and synchronizes follicular wave… Biology of reproduction 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT04157725 | Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro F | UNKNOWN | PHASE4 |
| NCT02496754 | Follicular Long GnRH Agonist Versus Antagonist Protocol in PCOS Women Undergoing in Vitro Fe | COMPLETED | NA |
| NCT07736261 | Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Resp | NOT_YET_RECRUITING | PHASE1, PHASE2 |
| NCT04854707 | An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data | COMPLETED | — |
| NCT02821819 | Random-start Ovarian Stimulation in Egg-donors (ROSE) | TERMINATED | PHASE4 |
Literature (8)
A new cetrorelix-based estrogen-free ovarian synchronization protocol for fixed-time artificial insemination in beef cattle — Theriogenology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41864162 · DOI 10.1016/j.theriogenology.2026.117904
Cetrorelix suppresses the dominant follicle and synchronizes follicular waves and ovulation in cattle† — Biology of reproduction 2026
To determine the effects of a GnRH antagonist on ovarian function in cattle, we tested the hypotheses that cetrorelix will (1) cause regression of the extant dominant follicle by altering gonadotrophin secretion and (2) induce a new follicular wave emergence at a consistent time after treatment. In Experiment 1, heifers were given 1.5 mg cetrorelix im on Days 1-2 (Day 0 = wave emergence), Days 3-4, and Days 6-7, or normal saline (Control, n = 8 per group). The dominant follicle was smaller and regressed earlier in groups treated with cetrorelix on Days 1-2 or Days 3-4 than in Controls (P = 0.01). Plasma LH concentrations were lower (P = 0.04) for 3 days after treatment, and the pre-wave surge in FSH occurred earlier in groups treated with cetrorelix on Days 1-2 or Days 3-4 than Controls (P = 0.01). Corpus luteum diameter was smaller (P = 0.01) in the cetrorelix groups, but luteal vascula…
open access ↗ · PMID 41395811 · DOI 10.1093/biolre/ioaf276
GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis — Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42152207 · DOI 10.29271/jcpsp.2026.05.654
Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation syndrome: A cross-sectional study — International journal of reproductive biomedicine 2026
BackgroundOvarian hyperstimulation syndrome (OHSS) is a severe iatrogenic disorder resulting from controlled ovarian stimulation. The administration of a gonadotropin-releasing hormone antagonist (cetrorelix) during the luteal phase is a practical approach for preventing OHSS.ObjectiveThis study aimed to evaluate the efficacy and safety of different cetrorelix regimens for preventing OHSS in high-risk groups.Materials and methodsIn this cross-sectional study, data of 271 women with a high-risk profile for OHSS presented to the Infertility Center of Kosar hospital, Urmia, Iran from March 2023 and March 2025 and those who underwent intracytoplasmic sperm injection were extracted from their medical records. Participants were given prophylactic luteal-phase cetrorelix regimen of [dose redacted] twice daily (BID group, n = 101), 0.5 mg 3 times daily (TDS group, n = 38), or 0.75 mg TDS group (n = 102).…
open access ↗ · PMID 42312112 · DOI 10.18502/ijrm.v24i4.21173
Cetrorelix promotes cell apoptosis via the PI3K-AKT-FOXO1 pathway in epithelial ovarian cancer — Frontiers in oncology 2025
IntroductionEpithelial ovarian cancer (EOC) has a dismal prognosis, and recent therapeutic advancements have been limited. The aim of our study was to clarify the role and mechanism of cetrorelix in EOC apoptosis and to evaluate the clinical relevance of GnRHR, AKT, and FOXO1 in EOC patients.MethodsApoptosis was assessed using flow cytometry, Hoechst staining, and Western blotting. FOXO1, p-AKT and GnRHR knockdown via siRNA was performed to reverse cetrorelix-induced apoptosis. Mechanistic insights were explored using apoptosis gene PCR arrays, qRT-PCR, and Western blotting. In vivo efficacy was tested in a xenograft mouse model. Immunohistochemistry (IHC) was used to assess GnRHR, AKT,p-AKT and FOXO1 expression in EOC tissues, and survival analysis was performed using Kaplan-Meier and Cox regression analyses.ResultsCetrorelix facilitated EOC apoptosis both in vitro and in a xenograft mo…
open access ↗ · PMID 41458598 · DOI 10.3389/fonc.2025.1631576
Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats — AAPS PharmSciTech 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42243608 · DOI 10.1208/s12249-026-03430-6
Effect of a GnRH antagonist on the fate of the dominant ovarian follicle and the emergence of the next follicular wave in alpacas — Theriogenology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41248592 · DOI 10.1016/j.theriogenology.2025.117733
Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach — Journal of peptide science : an official publication of the European Peptide Society 2025
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 40386934 · DOI 10.1002/psc.70030
Related
Glucagon
hormone · 8 citations
Ghrelin
hormone · 8 citations
Oxytocin
hormone · 8 citations
Vasopressin
hormone · 8 citations
Gonadorelin
hormone · 8 citations
Kisspeptin-10
hormone · 8 citations